XOMA (US) LLC Unveils Strategy, Provides Update On NEUPREX(R); European Effort Advances Toward Orphan Drug Designation And Approval Under Exceptional Circumstances; US Trials Progress

XOMA Ltd. (Nasdaq:XOMA) today unveiled its strategy and provided an update on the status of its efforts to advance NEUPREX(R) (opebacan) toward regulatory approval in Europe and the US in multiple disease indications.